David Hutton

Canton, North Olmsted

Executive Editor at Ophthalmology Times

Managing Editor of Ophthalmology Times, focusing on cutting edge advancements in ophthalmology.

Featured in: Favicon

ophthalmologytimes.com (+1) Favicon

newsbreak.com Favicon

plasticsnews.com Favicon

drugtopics.com Favicon

optometrytimes.com Favicon

plasticsnewseurope.com Favicon

modernretina.com Favicon

cgtlive.com Favicon

ajmc.com

ourcommunitynow.com

Articles

NYU Ophthalmology Journal Club: Exploring longterm success of DSO for Fuchs Dystrophy with Deepinder Dhaliwal, MD, LAc

Dec 26, 2024 | ophthalmologytimes.com | David Hutton

Deepinder Dhaliwal, MD, LAc, discusses longterm outcomes of Descemet Stripping Only (DSO) for Fuchs dystrophy at NYU's Journal Club, highlighting a 77% success rate at 5 years and evolving techniques.
Bausch + Lomb acquires ELIOS system, expanding glaucoma treatment options

Dec 11, 2024 | ophthalmologytimes.com | David Hutton

Bausch + Lomb Corp. today announced that an affiliate has acquired Elios Vision Inc., developer of the ELIOS procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser.
IL-6 and its role in thyroid eye disease

Dec 10, 2024 | ophthalmologytimes.com | David Hutton

In an interview with Ophthalmology Times, Alon Kahana, MD, PhD, discussed interleukin-6 (IL-6), a signaling molecule crucial in regulating the immune system and its role in autoimmune diseases, particularly thyroid eye disease (TED). IL-6 influences T cells, B cells, and inflammatory cells, driving immune processes that can be beneficial in infections but harmful in autoimmune conditions.
ViaLase, John A. Moran Eye Center unveil research partnership to spark glaucoma research, innovation

Dec 10, 2024 | ophthalmologytimes.com | David Hutton

ViaLase Inc. announced a research partnership with the John A. Moran Eye Center at the University of Utah, home to the Alan S. Crandall Center for Glaucoma Innovation. The collaboration will investigate the aqueous outflow dynamics of ViaLase’s novel laser procedure, using Moran's advanced iPerfusion technology. The ViaLase laser procedure delivers precise femtosecond laser pulses, guided by micron-accurate imaging, to create apertures through the trabecular meshwork (TM) and into Schlemm’s canal.
Part 7: Advice from the experts: Helpful information for current residents

Dec 10, 2024 | ophthalmologytimes.com | Sydney Crago |Martin Harp |Sheryl Stevenson |David Hutton

CommentaryVideoDecember 10, 2024Author(s):,In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers. In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers. Editor's note: The below transcript has been lightly edited for clarity.
Galimedix Therapeutics initiates Phase 1 trial of oral GAL-101

Dec 10, 2024 | optometrytimes.com | David Hutton

Galimedix Therapeutics Inc. announced the initiation of dosing in its phase 1 clinical trial evaluating oral GAL-101, an amyloid beta (Aβ) aggregation modulator. This trial is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of the orally administered therapy. The phase 1 study aims to enroll up to 40 healthy volunteers in the single ascending dose (SAD) cohort and 32 participants in the multiple ascending dose (MAD) cohort.
Nona Biosciences and Kodiak Sciences partner to develop novel antibodies for ophthalmic diseases

Dec 10, 2024 | ophthalmologytimes.com | David Hutton

Nona Biosciences has announced a strategic collaboration with Kodiak Sciences Inc. aimed at advancing the discovery of innovative multi-target antibodies for the treatment of ophthalmic diseases. This partnership will utilize Nona's proprietary Harbour Mice platform, a technology for generating fully human antibodies.
Beacon Therapeutics announces positive 3-month data from Phase 2 DAWN trial of AGTC-501 in patients with X-linked retinitis pigmentosa

Dec 9, 2024 | ophthalmologytimes.com | David Hutton

Beacon Therapeutics presented 3-month interim safety and efficacy data from the Phase 2 DAWN trial of laru-zova (AGTC-501) for X-linked retinitis pigmentosa (XLRP) at the FLORetina ICOOR 2024 meeting in Florence, Italy.
Study finds increased air pollution leads to surge in daily eye clinic visits

Dec 8, 2024 | ophthalmologytimes.com | David Hutton

The number of daily patient visits at the Sue Anschutz-Rodgers Eye Center significantly rise when ambient particulate matter (PM) levels in the Denver metro region increase, according to a study conducted by ophthalmology researchers at the University of Colorado School of Medicine.
Part 6: Advice from the experts: Helpful information for current residents

Dec 8, 2024 | ophthalmologytimes.com | Sydney Crago |Martin Harp |Sheryl Stevenson |David Hutton

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers. Editor's note: The below transcript has been lightly edited for clarity. So I think one thing is to remember to have a high index of suspicion for thyroid eye disease. Thyroid eye disease is the most common cause of either unilateral or bilateral proptosis in adults.